Cilostazol reduces restenosis in infrapopliteal angioplasty

Original title: Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia Reference: Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581.

Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory. 

The use of stents and paclitaxel eluting balloons seems promising; however using it in all infrapopliteal lesions is not affordable. The aim of this study that included 63 patients (32 in the cilostazol group and 31 in the control group) was to assess whether cilostazol reduces binary restenosis at three months follow up. All patients presented critical limb ischemia.

Cilostazol group showed lower binary restenosis (56% vs. 86%, p=0,015), lower reocclusion (20,5% vs. 42,1%, p=0,02) and lower target lesion revascularization (27,5% vs 49,1%) compared to the control group. Looking at clinical outcomes of affected limbs, instead of the angiographical lesions, no differences were found between the two groups, as regards both ulcer healing and member salvage.

Conclusion 

Cilostazol could reduce restenosis and revascularization after infrapopliteal angioplasty in patients with critical limb ischemia.

Editorial Comment:

This work has several important limitations such as the fact that it was a retrospective analysis and that cilostazol was indicated following operator’s criterion. The small number of patients enrolled in this study is also a limitation, as well as follow at three months. On the other hand, this study shows real life results (they did not use drug eluting stents or balloons) of infrapopliteal limb salvage angioplasty where all additional measures can have relative impact in the context of such poor results. No one can doubt that, though promising, cilostazol needs further randomized studies assessment.

SOLACI.ORG

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...